Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody

被引:23
|
作者
Hung Nguyen [1 ]
Pham Dang Lan [2 ,3 ]
Nissley, Daniel A. [4 ]
O'Brien, Edward P. [5 ,6 ,7 ]
Li, Mai Suan [1 ]
机构
[1] Polish Acad Sci, Inst Phys, PL-02668 Warsaw, Poland
[2] Inst Computat Sci & Technol, Life Sci Lab, Ho Chi Minh City, Vietnam
[3] VNUHCM Univ Sci, Fac Phys & Engn Phys, Ho Chi Minh City, Vietnam
[4] Univ Oxford, Dept Stat, Oxford Prot Bioinformat Grp, Oxford OX1 2JD, England
[5] Penn State Univ, Dept Chem, University Pk, PA 16802 USA
[6] Penn State Univ, Huck Inst Life Sci, Bioinformat & Genom Grad Program, University Pk, PA 16802 USA
[7] Penn State Univ, Inst Computat & Data Sci, University Pk, PA 16802 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
STEERED MOLECULAR-DYNAMICS; CORONAVIRUS SPIKE PROTEIN; SARS-CORONAVIRUS; FORCE-FIELD; WEB SERVER; ACTIVATION; TRANSITION; VARIANTS; MODELS; LIGAND;
D O I
10.1021/acs.jpcb.1c03639
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
A structural understanding of the mechanism by which antibodies bind SARS-CoV-2 at the atomic level is highly desirable as it can tell the development of more effective antibodies to treat Covid-19. Here, we use steered molecular dynamics (SMD) and coarse-grained simulations to estimate the binding affinity of the monoclonal antibodies CR3022 and 4A8 to the SARS-CoV-2 receptor-binding domain (RBD) and SARS-CoV-2 N-terminal domain (NTD). Consistent with experiments, our SMD and coarse-grained simulations both indicate that CR3022 has a higher affinity for SARS-CoV-2 RBD than 4A8 for the NTD, and the coarse-grained simulations indicate the former binds three times stronger to its respective epitope. This finding shows that CR3022 is a candidate for Covid-19 therapy and is likely a better choice than 4A8. Energetic decomposition of the interaction energies between these two complexes reveals that electrostatic interactions explain the difference in the observed binding affinity between the two complexes. This result could lead to a new approach for developing anti-Covid-19 antibodies in which good candidates must contain charged amino acids in the area of contact with the virus.
引用
收藏
页码:7368 / 7379
页数:12
相关论文
共 31 条
  • [21] De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike receptor binding domain (RBD)
    Boorla, Veda Sheersh
    Chowdhury, Ratul
    Ramasubramanian, Ranjani
    Ameglio, Brandon
    Frick, Rahel
    Gray, Jeffrey J.
    Maranas, Costas D.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2023, 91 (02) : 196 - 208
  • [22] HIGHER BINDING AFFINITIES OF HOPEA PHYTOCOMPOUNDS TO THE SARS-COV-2 MAIN PROTEASE THAN KNOWN ANTIVIRALS: MOLECULAR DOCKING AND DYNAMIC SIMULATION STUDY
    Rozani, Nur hannani ahmad
    Jusoh, Siti azma
    Abd Majid, Fadzilah Adibah
    Mokhtar, Nur'Ainun
    Khairudin, Nurul bahiya ahmad
    Tap, Fatahiya mohamed
    JOURNAL OF ENGINEERING SCIENCE AND TECHNOLOGY, 2024, 19 (05): : 1751 - 1774
  • [23] Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on "Pseudovirus-like" Nanoparticles
    Gaikwad, Hanmant
    Li, Yue
    Wang, Guankui
    Li, Ronghui
    Dai, Shaodong
    Rester, Cody
    Kedl, Ross
    Saba, Laura
    Banda, Nirmal K.
    Scheinman, Robert, I
    Patrick, Casey
    Mallela, Krishna M. G.
    Moghimi, S. Moein
    Simberg, Dmitri
    ACS NANO, 2022, 16 (06) : 8704 - 8715
  • [24] Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination
    Li, Zhe
    Obraztsova, Anna
    Shang, Fuwei
    Oludada, Opeyemi Ernest
    Malapit, Joshua
    van Straaten, Monique
    Stebbins, Erec
    Murugan, Rajagopal
    Wardemann, Hedda
    IMMUNITY, 2024, 57 (09) : 2191 - 2201.e5
  • [25] Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
    Shi, Juan
    Jin, Xiaoxiao
    Ding, Yan
    Liu, Xiaotao
    Shen, Anran
    Wu, Yandan
    Peng, Min
    Shen, Chuanlai
    VACCINES, 2021, 9 (12)
  • [26] A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
    Beaudoin-Bussieres, Guillaume
    Chen, Yaozong
    Ullah, Irfan
    Prevost, Jeremie
    Tolbert, William D.
    Symmes, Kelly
    Ding, Shilei
    Benlarbi, Mehdi
    Gong, Shang Yu
    Tauzin, Alexandra
    Gasser, Romain
    Chatterjee, Debashree
    Vezina, Dani
    Goyette, Guillaume
    Richard, Jonathan
    Zhou, Fei
    Stamatatos, Leonidas
    McGuire, Andrew T.
    Charest, Hughes
    Roger, Michel
    Pozharski, Edwin
    Kumar, Priti
    Mothes, Walther
    Uchil, Pradeep D.
    Pazgier, Marzena
    Finzi, Andres
    CELL REPORTS, 2022, 38 (07):
  • [27] XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
    Vanhove, Bernard
    Marot, Stephane
    So, Ray T.
    Gaborit, Benjamin
    Evanno, Gwenaelle
    Malet, Isabelle
    Lafrogne, Guillaume
    Mevel, Edwige
    Ciron, Carine
    Royer, Pierre-Joseph
    Lheriteau, Elsa
    Raffi, Francois
    Bruzzone, Roberto
    Mok, Chris Ka Pun
    Duvaux, Odile
    Marcelin, Anne-Genevieve
    Calvez, Vincent
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [28] COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
    Faizan Zarreen Simnani
    Dibyangshee Singh
    Ramneet Kaur
    3 Biotech, 2022, 12
  • [29] COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
    Simnani, Faizan Zarreen
    Singh, Dibyangshee
    Kaur, Ramneet
    3 BIOTECH, 2022, 12 (01)
  • [30] XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants (vol 12, 761250, 2021)
    Vanhove, Bernard
    Marot, Stephane
    So, Ray T. T.
    Gaborit, Benjamin
    Evanno, Gwenaelle
    Malet, Isabelle
    Lafrogne, Guillaume
    Mevel, Edwige
    Ciron, Carine
    Royer, Pierre-Joseph
    Lheriteau, Elsa
    Raffi, Francois
    Bruzzone, Roberto
    Mok, Chris Ka Pun
    Duvaux, Odile
    Marcelin, Anne-Genevieve
    Calvez, Vincent
    FRONTIERS IN IMMUNOLOGY, 2023, 14